Accumulating evidence indicates that cellular senescence is closely associated with osteoarthritis. However, there is limited research on the mechanisms underlying fibroblast-like synoviocyte senescence and its impact on osteoarthritis progression. Here, we elucidate a positive correlation between fibroblast-like synoviocyte senescence and osteoarthritis progression and reveal that GATD3A deficiency induces fibroblast-like synoviocyte senescence.
View Article and Find Full Text PDFBMC Musculoskelet Disord
December 2024
Background: Surgical site infection (SSI) is a serious complication of spine surgery, leading to prolonged hospital stays, re-operations, and economic losses. The aim of the study was to explore the types and quantities of pathogenic bacteria involved, the incidence of SSI, and to identify the independent risk factors and direct economic impact on patients with postoperative SSI in spine surgery.
Methods: The medical records of spine surgery patients from January 2023 to April 2024 at two hospitals in Xinjiang were retrospectively reviewed.
The real-time detection of gaseous HO and its typical isotopic molecules, e.g., HO, DO, HDO, and HTO, is highly desirable in many fundamental scientific studies and practical monitoring, such as mechanistic studies of HO-involved chemical reactions and radiation risk warning of abnormal HTO emissions.
View Article and Find Full Text PDFThe main pathogenic mechanism of HIV-associated neurocognitive disorders (HAND) is neuronal apoptosis induced by inflammatory mediators, in which microglial inflammation plays a crucial role. However, the exact pathogenic mechanism remains unclear. Previous studies have shown that the HIV-1 gp120 V3 loop can trigger inflammation in CHME-5 microglia.
View Article and Find Full Text PDFHR/HER2-low breast cancer is a significant subgroup of conventional HR/HER2-negative breast cancer, and combination of CDK4/6 inhibitor and endocrine therapy is the standard first-line and second-line treatments for advanced HR/HER2-low breast cancer. Nevertheless, it remains uncertain whether HER2 signaling affects the effectiveness of CDK4/6 inhibitor administered in combination with endocrine therapy for HR/HER2-low breast cancer and suitable intervention measures. This study revealed poor efficacy for CDK4/6 inhibitor combined with endocrine therapy for HR/HER2-low breast cancer in vitro and in vivo models.
View Article and Find Full Text PDF